Free Trial
NASDAQ:SRZN

Surrozen (SRZN) Stock Price, News & Analysis

Surrozen logo
$9.96 -0.52 (-4.96%)
Closing price 05/2/2025 03:59 PM Eastern
Extended Trading
$9.66 -0.30 (-2.96%)
As of 05/2/2025 04:01 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Surrozen Stock (NASDAQ:SRZN)

Key Stats

Today's Range
$9.96
$10.95
50-Day Range
$8.89
$12.45
52-Week Range
$6.00
$18.17
Volume
7,846 shs
Average Volume
20,945 shs
Market Capitalization
$32.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$38.50
Consensus Rating
Buy

Company Overview

Surrozen, Inc., a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043, a hepatocyte-specific R-spondin mimetic bispecific fusion protein, which is in Phase 1b clinical trial for the treatment of severe liver diseases, including alcohol-associated hepatitis. The company develops SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies. Surrozen, Inc. is based in South San Francisco, California.

Surrozen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
76th Percentile Overall Score

SRZN MarketRank™: 

Surrozen scored higher than 76% of companies evaluated by MarketBeat, and ranked 401st out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Surrozen has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Surrozen has only been the subject of 1 research reports in the past 90 days.

  • Read more about Surrozen's stock forecast and price target.
  • Earnings Growth

    Earnings for Surrozen are expected to decrease in the coming year, from ($8.49) to ($10.71) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Surrozen is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Surrozen is -0.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Surrozen has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Surrozen's valuation and earnings.
  • Percentage of Shares Shorted

    4.90% of the float of Surrozen has been sold short.
  • Short Interest Ratio / Days to Cover

    Surrozen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Surrozen has recently decreased by 26.08%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Surrozen does not currently pay a dividend.

  • Dividend Growth

    Surrozen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.90% of the float of Surrozen has been sold short.
  • Short Interest Ratio / Days to Cover

    Surrozen has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Surrozen has recently decreased by 26.08%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Surrozen has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.
  • Insider Buying vs. Insider Selling

    In the past three months, Surrozen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,999,991.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    45.18% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    66.57% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Surrozen's insider trading history.
Receive SRZN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter.

SRZN Stock News Headlines

Surrozen files to sell 5.21M shares of common stock for holders
Surrozen reports FY24 EPS ($21.67) vs. ($21.33) last year
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Headlines

SRZN Stock Analysis - Frequently Asked Questions

Surrozen's stock was trading at $14.35 at the beginning of 2025. Since then, SRZN shares have decreased by 30.6% and is now trading at $9.96.
View the best growth stocks for 2025 here
.

Surrozen, Inc. (NASDAQ:SRZN) posted its quarterly earnings data on Monday, March, 31st. The company reported ($9.10) earnings per share for the quarter, missing the consensus estimate of ($2.54) by $6.56. The firm had revenue of $0.66 million for the quarter.

Surrozen's stock reverse split on the morning of Thursday, December 14th 2023. The 1-15 reverse split was announced on Thursday, December 14th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, December 14th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Surrozen investors own include ACADIA Pharmaceuticals (ACAD), Marvell Technology (MRVL), HubSpot (HUBS), Avidity Biosciences (RNA), Adverum Biotechnologies (ADVM), Alpha and Omega Semiconductor (AOSL) and

Company Calendar

Last Earnings
3/31/2025
Today
5/03/2025
Next Earnings (Estimated)
5/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:SRZN
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$38.50
High Stock Price Target
$45.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+286.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-43,040,000.00
Pretax Margin
-444.38%

Debt

Sales & Book Value

Annual Sales
$10.66 million
Price / Cash Flow
N/A
Book Value
$18.39 per share
Price / Book
0.54

Miscellaneous

Free Float
1,836,000
Market Cap
$32.68 million
Optionable
Not Optionable
Beta
0.69
Reduce the Risk Cover

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

This page (NASDAQ:SRZN) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners